Ranitidine

Ranitidine

Ranitidine; 66357-35-5; ZANTAC; Gastrosedol; Coralen

Aciba, Acidom-O, Aciloc, Aciloc-RD, Acispas, Actispas-R, Advene, Alcirid-O, Alotac, Amylocarb, Ancid, Andom, Antac, Asispas, Avispas, Aztec, Aztec-D, Becotac, Candotac-O, Consec, Coretac, Cotac, Cycloran, Cypatec, Cypatec-D, Din, Dom-R, Dom-T, Domar, Domar-O, Domny-R, Doran-O, Emtec, Entac, Fydom-R, Fydon-R, Gaspaz, Giran, Healcer, Helkoss, Helkoss-D, Histac, Hytide, Intac, Kamtac, Lantac, Lydin, Manotac, Manotac Plus, Meditin

dimethyl [(5-{[(2-{[(E)-1-(methylamino)-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine

Hepatic metabolism.

It is a histamine H2-receptor antagonist used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells.

The recommended dose is 300 mg at bedtime or 150 mg twice daily for 4-8 weeks depending on the condition per oral.

Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

Headache, dizziness hepatitis thrombocytopaenia, confusion, leucopaenia, hypersensitivity, impotence, gynaecomastia, somnolence, vertigo, hallunications. Anaphylaxis, hypersensitivity reactions.

• Antacids may interfere with absorption.
• Smoking may decrease the plasma levels of ranitidine.
• GI absorption of ketoconazole may be decreased.
• May cause an increase in the bioavailibility of furosemide.

Porphyria

59° to 86°F

Molecular weight

314.404

Molecular formula

C13H22N4O3S

CAS number

66357-35-5

Precautions

• Exclude malignancy before treating gastric ulcer.
• Renal & hepatic impairment.
• Infants, pregnancy & lactation.